{
    "nctId": "NCT00795678",
    "briefTitle": "Chemotherapeutic Agents in Brain/Breast",
    "officialTitle": "Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Concentration of drug",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast carcinoma with \u2265 1 suspected or known parenchymal brain metastases for which surgical resection or biopsy is clinically indicated\n* Treating oncologist must agree that the patient would derive clinical benefit from receiving \u2265 1 of the following study agents:\n\n  * Capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, trastuzumab (Herceptin\u00ae), or vinorelbine ditartrate\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Karnofsky performance status 50-100%\n* Life expectancy \u2265 3 months\n* Absolute granulocyte count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 10 g/dL\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin (total) \u2264 1.5 times ULN\n* AST \u2264 3 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for three months after completion of study treatment\n* No severe NYHA class III-IV cardiac insufficiency with uncontrolled and/or unstable cardiac or coronary artery disease\n* No history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits\n\nPRIOR CONCURRENT THERAPY:\n\n* No toxicity \\> grade 2 from prior chemotherapy or radiotherapy remains at the time of study entry\n* At least 60 days since prior bevacizumab\n* At least 4 weeks since prior cranial radiotherapy\n* At least 3 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C)\n* At least 2 weeks since prior non-cytotoxic drugs (e.g., small molecule-targeted drugs)\n* No concurrent experimental therapies\n* Concurrent hormone therapy and/or trastuzumab (Herceptin\u00ae) allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}